Tadalafil in patients with COPD-associated pulmonary hypertension: effects on exercise capacity
Phase of Trial: Phase II
Latest Information Update: 01 Nov 2013
Price : $35 *
At a glance
- Drugs Tadalafil (Primary)
- Indications Pulmonary hypertension
- Focus Therapeutic Use
- Acronyms 3P
- 01 Nov 2013 New trial record
- 11 Sep 2013 Results presented at the 23rd Annual Congress of the European Respiratory Society.
- 10 Sep 2013 Primary endpoint 'Six-minute-walking-distance' has not been met.